Cargando…
Patched-2 functions to limit Patched-1 deficient skin cancer growth
PURPOSE: Basal cell carcinoma (BCC) is one of the most common skin cancers, and is typically driven by an aberrantly activated Hedgehog (Hh) pathway. The Hh pathway is regulated by interactions between the Patched-1 (Ptch1) and Smoothened (Smo) receptors. Smo is an activating receptor and is subject...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105176/ https://www.ncbi.nlm.nih.gov/pubmed/29869097 http://dx.doi.org/10.1007/s13402-018-0381-9 |
_version_ | 1783349612791201792 |
---|---|
author | Veenstra, Veronique L. Dingjan, Ilse Waasdorp, Cynthia Damhofer, Helene van der Wal, Allard C. van Laarhoven, Hanneke W. Medema, Jan Paul Bijlsma, Maarten F. |
author_facet | Veenstra, Veronique L. Dingjan, Ilse Waasdorp, Cynthia Damhofer, Helene van der Wal, Allard C. van Laarhoven, Hanneke W. Medema, Jan Paul Bijlsma, Maarten F. |
author_sort | Veenstra, Veronique L. |
collection | PubMed |
description | PURPOSE: Basal cell carcinoma (BCC) is one of the most common skin cancers, and is typically driven by an aberrantly activated Hedgehog (Hh) pathway. The Hh pathway is regulated by interactions between the Patched-1 (Ptch1) and Smoothened (Smo) receptors. Smo is an activating receptor and is subject to inhibition by Ptch1. Following ligand binding to Ptch1, its inhibitory action is relieved and pathway activation occurs. This receptor interaction is pivotal to restraining uncontrolled cellular growth. Both receptors have been found to be frequently mutated in BCCs. Ptch2 is a Ptch1 paralog that exhibits overlapping functions in both normal development and tissue homeostasis. As yet, its contribution to cancer growth is poorly defined. Here we set out to assess how Ptch2 inhibits BCC growth. METHODS: We used several in vitro readouts for transcriptional and chemotactic Hh signaling in BCC-derived ASZ001 cells, and a novel xenograft model to assess in vivo BCC tumor growth. Gene editing by TALEN was used to untangle the different Ptch2-dependent responses to its ligand sonic hedgehog (Shh). RESULTS: We first defined the signaling competence of Ptch2 in Ptch1-deficient ASZ001 cells in vitro, and found that Ptch2 ligand binding drives their migration rather than eliciting a transcriptional response. We found that subsequent targeting of Ptch2 abrogated the chemotaxic effect. Next, we tested the contribution of Ptch2 to in vivo tumor growth using a xenograft model and found that reduced Ptch function results in increased tumor growth, but that selective pressure appatently acts against complete Ptch2 ablation. CONCLUSIONS: We conclude that like Ptch1, Ptch2 exerts a tumor-suppressive function in BCC cells, and that after targeting of both paralogs, ligand-independent activation of the Hh pathway contributes to tumor growth. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13402-018-0381-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6105176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-61051762018-08-30 Patched-2 functions to limit Patched-1 deficient skin cancer growth Veenstra, Veronique L. Dingjan, Ilse Waasdorp, Cynthia Damhofer, Helene van der Wal, Allard C. van Laarhoven, Hanneke W. Medema, Jan Paul Bijlsma, Maarten F. Cell Oncol (Dordr) Original Paper PURPOSE: Basal cell carcinoma (BCC) is one of the most common skin cancers, and is typically driven by an aberrantly activated Hedgehog (Hh) pathway. The Hh pathway is regulated by interactions between the Patched-1 (Ptch1) and Smoothened (Smo) receptors. Smo is an activating receptor and is subject to inhibition by Ptch1. Following ligand binding to Ptch1, its inhibitory action is relieved and pathway activation occurs. This receptor interaction is pivotal to restraining uncontrolled cellular growth. Both receptors have been found to be frequently mutated in BCCs. Ptch2 is a Ptch1 paralog that exhibits overlapping functions in both normal development and tissue homeostasis. As yet, its contribution to cancer growth is poorly defined. Here we set out to assess how Ptch2 inhibits BCC growth. METHODS: We used several in vitro readouts for transcriptional and chemotactic Hh signaling in BCC-derived ASZ001 cells, and a novel xenograft model to assess in vivo BCC tumor growth. Gene editing by TALEN was used to untangle the different Ptch2-dependent responses to its ligand sonic hedgehog (Shh). RESULTS: We first defined the signaling competence of Ptch2 in Ptch1-deficient ASZ001 cells in vitro, and found that Ptch2 ligand binding drives their migration rather than eliciting a transcriptional response. We found that subsequent targeting of Ptch2 abrogated the chemotaxic effect. Next, we tested the contribution of Ptch2 to in vivo tumor growth using a xenograft model and found that reduced Ptch function results in increased tumor growth, but that selective pressure appatently acts against complete Ptch2 ablation. CONCLUSIONS: We conclude that like Ptch1, Ptch2 exerts a tumor-suppressive function in BCC cells, and that after targeting of both paralogs, ligand-independent activation of the Hh pathway contributes to tumor growth. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13402-018-0381-9) contains supplementary material, which is available to authorized users. Springer Netherlands 2018-06-04 2018 /pmc/articles/PMC6105176/ /pubmed/29869097 http://dx.doi.org/10.1007/s13402-018-0381-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Veenstra, Veronique L. Dingjan, Ilse Waasdorp, Cynthia Damhofer, Helene van der Wal, Allard C. van Laarhoven, Hanneke W. Medema, Jan Paul Bijlsma, Maarten F. Patched-2 functions to limit Patched-1 deficient skin cancer growth |
title | Patched-2 functions to limit Patched-1 deficient skin cancer growth |
title_full | Patched-2 functions to limit Patched-1 deficient skin cancer growth |
title_fullStr | Patched-2 functions to limit Patched-1 deficient skin cancer growth |
title_full_unstemmed | Patched-2 functions to limit Patched-1 deficient skin cancer growth |
title_short | Patched-2 functions to limit Patched-1 deficient skin cancer growth |
title_sort | patched-2 functions to limit patched-1 deficient skin cancer growth |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105176/ https://www.ncbi.nlm.nih.gov/pubmed/29869097 http://dx.doi.org/10.1007/s13402-018-0381-9 |
work_keys_str_mv | AT veenstraveroniquel patched2functionstolimitpatched1deficientskincancergrowth AT dingjanilse patched2functionstolimitpatched1deficientskincancergrowth AT waasdorpcynthia patched2functionstolimitpatched1deficientskincancergrowth AT damhoferhelene patched2functionstolimitpatched1deficientskincancergrowth AT vanderwalallardc patched2functionstolimitpatched1deficientskincancergrowth AT vanlaarhovenhannekew patched2functionstolimitpatched1deficientskincancergrowth AT medemajanpaul patched2functionstolimitpatched1deficientskincancergrowth AT bijlsmamaartenf patched2functionstolimitpatched1deficientskincancergrowth |